Benznidazole for the treatment of Chagas disease

References

• Pérez-Molina JA, Molina I. Chagas disease. Lancet. 2018;391(10115):p. 82–94.
   Web of Science ®Google Scholar
• Requena-Méndez A, Aldasoro E, de Lazzari E, et al. Prevalence of Chagas disease in latin-american migrants living in Europe: a systematic review and meta-analysis. PLoS Negl Trop Dis. 2015;9(2):e0003540.
   PubMed Web of Science ®Google Scholar
• Gascon J, Bern C, Pinazo MJ. Chagas disease in Spain, the United States and other non-endemic countries. Acta Trop. 2010;115(1–2):22–27.
   PubMed Web of Science ®Google Scholar
• Bern C, Montgomery SP. An estimate of the burden of Chagas disease in the United States. Clin Infect Dis. 2009;49(5):e52–4.
   PubMed Web of Science ®Google Scholar
• Strasen J, Williams T, Ertl G, et al. Epidemiology of chagas disease in Europe: many calculations, little knowledge. Clin. Res. Cardiol. Clin Res Cardiol. 2014;103(1):1–10.
   Google Scholar
• Bern C, Montgomery SP, Herwaldt BL, et al. Evaluation and treatment of chagas disease in the United States: a systematic review. J Am Med Assoc. 2007;298(18):2171–2181.
   PubMed Web of Science ®Google Scholar
• Russomando G, De Tomassone MMC, De Guillen I, et al. Treatment of congenital chagas’ disease diagnosed and followed up by the polymerase chain reaction. Am J Trop Med Hyg. 1998;59(3): 487–491.
   PubMed Web of Science ®Google Scholar
• Schijman AG, Altcheh J, Burgos JM, et al. Aetiological treatment of congenital Chagas’ disease diagnosed and monitored by the polymerase chain reaction. J Antimicrob Chemother. 2003;52(3):441–449.
   PubMed Web of Science ®Google Scholar
• Cançado JR. Criteria of Chagas disease cure. Mem Inst Oswaldo Cruz. 1999;94(suppl 1):331–335.
   PubMedGoogle Scholar
• Pérez-Molina JA, Pérez-Ayala A, Moreno S, et al. Use of benznidazole to treat chronic Chagas’ disease: a systematic review with a meta-analysis. J Antimicrob Chemother. 2009;64(6):1139–1147.
   PubMed Web of Science ®Google Scholar
• Carlos J, Dias P, Novaes A, et al. 2nd Brazilian consensus on Chagas disease. Rev da Soc Bras Med Trop.. 2015;50(1):149.
   Google Scholar
• Pan American Health Organization. Guidelines for the diagnosis and treatment of Chagas disease. Washington, D.C: Pan American Healthcares Organization; 2019.
   Google Scholar
• de Salud AM. Guía para la atención al paciente infectado con Trypanosoma cruzi. Ministerio de Salud y Desarrollo Social, Ciudad autónoma de Buenos Aires; 2018.
   Google Scholar
• Álvarez MG, Vigliano C, Lococo B, et al. Prevention of congenital Chagas disease by benznidazole treatment in reproductive-age women. An observational study. Acta Trop. 2017;174:149–152.
   PubMed Web of Science ®Google Scholar
• Fabbro DL, Danesi E, Olivera V, et al. Trypanocide treatment of women infected with Trypanosoma cruzi and its effect on preventing congenital Chagas. PLoS Negl Trop Dis. 2014;8(11): e3312.
   PubMed Web of Science ®Google Scholar
• Moscatelli G, Moroni S, García-Bournissen F, et al. Prevention of congenital Chagas through treatment of girls and women of childbearing age. Mem Inst Oswaldo Cruz. 2015;110(4):507–509.
   PubMed Web of Science ®Google Scholar
• Murcia L, Simón M, Carrilero B, et al. Treatment of infected women of childbearing age prevents congenital Trypanosoma cruzi infection by eliminating the parasitemia detected by PCR. J Infect Dis. 2017;215(9):1452–1458.
   PubMed Web of Science ®Google Scholar
• Ciapponi A, Barreira F, Perelli L, et al. Fixed vs adjusted-dose benznidazole for adults with chronic Chagas disease without cardiomyopathy: a systematic review and meta-analysis. PLoS Negl Trop Dis. 2020;14(8):e0008529.
   PubMed Web of Science ®Google Scholar
• Pinazo MJ, Muñoz J, Posada E, et al. Tolerance of benznidazole in treatment of Chagas’ disease in adults. Antimicrob Agents Chemother. 2010;54(11): 4896–4899.
   PubMed Web of Science ®Google Scholar
• Aldasoro E, Posada E, Requena-Méndez A, et al. What to expect and when: benznidazole toxicity in chronic Chagas’ disease treatment. J Antimicrob Chemother. 2018;73(4):1060–1067.
   PubMed Web of Science ®Google Scholar
• Müller Kratz J, Garcia Bournissen F, Forsyth CJ, et al. Clinical and pharmacological profile of benznidazole for treatment of Chagas disease. Expert Rev Clin Pharmacol. 2018;11(10):943–957.
   PubMed Web of Science ®Google Scholar
• Hall BS, Wilkinson SR. Activation of benznidazole by trypanosomal type I nitroreductases results in glyoxal formation. Antimicrob Agents Chemother. 2012;56(1):115–123.
   PubMed Web of Science ®Google Scholar
• Wilkinson SR, Kelly JM. Trypanocidal drugs: mechanisms, resistance and new targets. Expert Rev Mol Med.. 2009;11: e31.
   PubMed Web of Science ®Google Scholar
• Caldas IS, Santos EG, Novaes RD. An evaluation of benznidazole as a Chagas disease therapeutic. Expert Opin Pharmacother. 2019;20(15):1797–1807.
   PubMed Web of Science ®Google Scholar
• Patterson S, Wyllie S. Nitro drugs for the treatment of trypanosomatid diseases: past, present, and future prospects. Trends Parasitol. 2014;30(6):289–298.
   PubMed Web of Science ®Google Scholar
• Rajão MA, Furtado C, Alves CL, et al. Unveiling Benznidazole’s mechanism of action through overexpression of DNA repair proteins in Trypanosoma cruzi. Environ Mol Mutagen. 2014;55(4):309–321.
   PubMed Web of Science ®Google Scholar
• Maya JD, Cassels BK, Iturriaga-Vásquez P, et al. Mode of action of natural and synthetic drugs against Trypanosoma cruzi and their interaction with the mammalian host. Comp Biochem Physiol Part A Mol Integr Physiol. 2007;146(4):601–620.
   PubMed Web of Science ®Google Scholar
• Alonso-Padilla J, Cortés-Serra N, Pinazo MJ, et al. Strategies to enhance access to diagnosis and treatment for Chagas disease patients in Latin America. Expert Rev Anti Infect Ther. 2019;17(3):145–157.
   PubMed Web of Science ®Google Scholar
• Raaflaub J, Ziegler WH. Single-dose pharmacokinetics of the trypanosomicide benznidazole in man. Arzneimittelforschung. 1979;29:1611–1614.
   PubMed Web of Science ®Google Scholar
• Raaflaub J. Multiple-dose kinetics of the trypanosomicide benznidazole in man. Arzneimittel-Forschung/Drug Res. 1980;30:2192–2194.
   PubMed Web of Science ®Google Scholar
• Molina I, Salvador F, Sánchez-Montalvá A, et al. Toxic profile of benznidazole in patients with chronic chagas disease: risk factors and comparison of the product from two different manufacturers. Antimicrob Agents Chemother. 2015;59(10):6125–6131.
   PubMed Web of Science ®Google Scholar
• Ferraz LR de M, Alves AÉG, Nascimento DDS da S, et al. Technological innovation strategies for the specific treatment of Chagas disease based on Benznidazole. Acta Trop. 2018;185:127–132.
   PubMed Web of Science ®Google Scholar
• Altcheh J, Moscatelli G, Mastrantonio G, et al. Population pharmacokinetic study of benznidazole in pediatric Chagas disease suggests efficacy despite lower plasma concentrations than in adults. PLoS Negl Trop Dis. 2014;8(5):e2907.
   PubMed Web of Science ®Google Scholar
• Pinazo MJ, Guerrero L, Posada E, et al. Benznidazole-related adverse drug reactions and their relationship to serum drug concentrations in patients with chronic chagas disease. Antimicrob Agents Chemother. 2013;57(1):390–395.
   PubMed Web of Science ®Google Scholar
• Molina I, Salvador F, Sánchez-Montalvá A, et al. Pharmacokinetics of benznidazole in healthy volunteers and implications in future clinical trials. Antimicrob Agents Chemother. 2017;61:e01912–16.
   PubMed Web of Science ®Google Scholar
• Soy D, Aldasoro E, Guerrero L, et al. Population pharmacokinetics of benznidazole in adult patients with Chagas disease. Antimicrob Agents Chemother. 2015;59(6):3342–3349.
   PubMed Web of Science ®Google Scholar
• Fernández ML, Marson ME, Ramirez JC, et al. Pharmacokinetic and pharmacodynamic responses in adult patients with chagas disease treated with a new formulation of benznidazole. Mem Inst Oswaldo Cruz. 2016;111(3):218–221.
   PubMed Web of Science ®Google Scholar
• Wiens MO, Kanters S, Mills E, et al. Systematic review and meta-analysis of the pharmacokinetics of benznidazole in the treatment of Chagas disease. Antimicrob Agents Chemother. 2016;60:7035–7042.
   PubMed Web of Science ®Google Scholar
• Molina I, Gómez I Prat J, Salvador F, et al. Randomized trial of posaconazole and benznidazole for chronic Chagas’ disease. N Engl J Med. 2014;370(20): 1899–1908.
   PubMed Web of Science ®Google Scholar
• Morillo CA, Waskin H, Sosa-Estani S, et al. Benznidazole and posaconazole in eliminating parasites in asymptomatic T. cruzi carriers: the STOP-CHAGAS Trial. J Am Coll Cardiol. 2017;69:(8):939–947.
   PubMed Web of Science ®Google Scholar
• Torrico F, Gascon J, Ortiz L, et al. Treatment of adult chronic indeterminate Chagas disease with benznidazole and three E1224 dosing regimens: a proof-of-concept, randomised, placebo-controlled trial. Lancet Infect Dis. 2018;18(4): 419–430.
   PubMed Web of Science ®Google Scholar
• Morillo CA, Marin-Neto JA, Avezum A, et al. Randomized trial of benznidazole for chronic Chagas’ Cardiomyopathy. N Engl J Med. 2015;373(14): 1295–1306.
   PubMed Web of Science ®Google Scholar
• Rassi A Jr, Marin Neto JA, Rassi A. Chronic Chagas cardiomyopathy: a review of the main pathogenic mechanisms and the efficacy of aetiological treatment following the BENznidazole Evaluation for Interrupting Trypanosomiasis (BENEFIT) trial. Mem Inst Oswaldo Cruz. 2017;112(3):224–235.
   PubMed Web of Science ®Google Scholar
• Cardoso CS, Ribeiro ALP, Oliveira CDL, et al. Beneficial effects of benznidazole in Chagas disease: NIH SaMi-Trop cohort study. PLoS Negl Trop Dis. 2018;12(11): e0006814.
   PubMed Web of Science ®Google Scholar
• Viotti R, Vigliano C, Lococo B, et al. Long-term cardiac outcomes of treating chronic Chagas disease with benznidazole versus no treatment. Ann Inter Med. 2006;144(10): 724.
   PubMed Web of Science ®Google Scholar
• Fabbro D, Velazquez E, Mendoza N, et al. Evaluación de ELISA F29 como marcador de eficacia del tratamiento etiológico en la enfermedad de Chagas. Parasitol Latinoam. 2007;623–4):103–111. [Article in Spanish].
   Google Scholar
• Chatelain E, Scandale I. Animal models of Chagas disease and their translational value to drug development. Expert Opin Drug Discov. 2020;00:1–22.
   Google Scholar
• Viotti R, Alarcón De Noya B, Araujo-Jorge T, et al. Towards a paradigm shift in the treatment of chronic chagas disease. Antimicrob. Agents Chemother. Antimicrob Agents Chemother. 2014;58(2):635–639.
   PubMed Web of Science ®Google Scholar
• Matos Ferreira AV, Segatto M, Menezes Z, et al. Evidence for Trypanosoma cruzi in adipose tissue in human chronic Chagas disease. Microbes Infect. 2011;13(12–13):1002–1005.
   PubMed Web of Science ®Google Scholar
• Lewis MD, Fortes Francisco A, Taylor MC, et al. Bioluminescence imaging of chronic Trypanosoma cruzi infections reveals tissue-specific parasite dynamics and heart disease in the absence of locally persistent infection. Cell Microbiol. 2014;16(9):1285–1300.
   PubMed Web of Science ®Google Scholar
• Ward AI, Lewis MD, Khan AA, et al. In vivo analysis of Trypanosoma cruzi persistence foci at single-cell resolution. MBio. 2020;11(4):e01242–20.
   PubMed Web of Science ®Google Scholar
• Resende BC, Oliveira ACS, Guañabens ACP, et al. The influence of recombinational processes to induce dormancy in Trypanosoma cruzi. Front Cell Infect Microbiol. 2020;10:5.
   PubMed Web of Science ®Google Scholar
• Sánchez-Valdéz FJ, Padilla A, Wang W, et al. Spontaneous dormancy protects Trypanosoma cruzi during extended drug exposure. Elife. 2018;7:e34039.
   PubMed Web of Science ®Google Scholar
• Barrett MP, Kyle DE, Sibley LD, et al. Protozoan persister-like cells and drug treatment failure. Nat Rev Microbiol. 2019;17(10):607–620.
   PubMed Web of Science ®Google Scholar
• Alonso-Padilla J, Abril M, Alarcón de Noya B, et al. Target product profile for a test for the early assessment of treatment efficacy in Chagas disease patients: an expert consensus. PLoS Negl Trop Dis. 2020;14(4): e0008035.
   PubMed Web of Science ®Google Scholar
• Cortes-Serra N, Losada-Galvan I, Pinazo MJ, et al. State-of-the-art in host-derived biomarkers of Chagas disease prognosis and early evaluation of anti-Trypanosoma cruzi treatment response. Mol Basis Dis. 2020;1866(7):165758.
   Google Scholar
• Sulleiro E, Muñoz-Calderon A, Schijman AG. Role of nucleic acid amplification assays in monitoring treatment response in chagas disease: usefulness in clinical trials. Acta Trop. 2019;199:105120.
   PubMed Web of Science ®Google Scholar
• Schijman AG. Molecular diagnosis of Trypanosoma cruzi. Acta Trop. 2018;184:59–66.
   PubMed Web of Science ®Google Scholar
• Parrado R, Ramirez JC, de la Barra A, et al. Usefulness of serial blood sampling and PCR replicates for treatment monitoring of patients with chronic Chagas disease. Antimicrob Agents Chemother. 2019;63(2):e01191–18.
   PubMed Web of Science ®Google Scholar
• Álvarez MG, Hernández Y, Bertocchi G, et al. New scheme of intermittent benznidazole administration in patients chronically infected with Trypanosoma cruzi: A pilot short-term follow-up study with adult patients. Antimicrob Agents Chemother. 2016;60(2): 833–837.
   PubMed Web of Science ®Google Scholar
• Molina-Morant D, Fernández ML, Bosch-Nicolau P, et al. Efficacy and safety assessment of different dosage of benznidazole for the treatment of Chagas disease in chronic phase in adults (MULTIBENZ study): study protocol for a multicenter randomized Phase II non-inferiority clinical trial. Trials. 2020. DOI:10.1186/s13063-020-4226-2.
   PubMed Web of Science ®Google Scholar
• Villar JC, Herrera VM, Pérez Carreño JG, et al. Nifurtimox versus benznidazole or placebo for asymptomatic Trypanosoma cruzi infection (Equivalence of Usual Interventions for Trypanosomiasis - EQUITY): study protocol for a randomised controlled trial. Trials. 2019;20(1):431.
   PubMed Web of Science ®Google Scholar
• Martínez-Peinado N, Cortes-Serra N, Losada-Galvan I, et al. Emerging agents for the treatment of Chagas disease: what is in the preclinical and clinical development pipeline? Expert Opin Investig Drugs. 2020;1–13. DOI:10.1080/13543784.2020.1793955.
   Web of Science ®Google Scholar
• Crespillo-Andújar C, Venanzi-Rullo E, López-Vélez R, et al. Safety profile of benznidazole in the treatment of chronic Chagas disease: experience of a referral centre and systematic literature review with meta-analysis. Drug Saf. 2018;41(11):1035–1048.
   PubMed Web of Science ®Google Scholar
• Sperandio da Silva GM, Mediano MFF, Hasslocher-Moreno AM, et al. Benznidazole treatment safety: the Médecins Sans Frontières experience in a large cohort of Bolivian patients with Chagas’ disease. J Antimicrob Chemother. 2017;72(9):2596–2601.
   PubMed Web of Science ®Google Scholar
• Hasslocher-Moreno AM, Do Brasil PEAA, de Sousa AS, et al. Safety of benznidazole use in the treatment of chronic Chagas’ disease. J Antimicrob Chemother. 2012;67(5):1261–1266.
   PubMed Web of Science ®Google Scholar
• Miller DA, Hernandez S, Rodriguez De Armas L, et al. Tolerance of benznidazole in a United States Chagas disease clinic. Clin Infect Dis. 2015;60(8):1237–1240.
   PubMed Web of Science ®Google Scholar
• Antinori S, Grande R, Bianco R, et al. High frequency of adverse reactions and discontinuation with benznidazole treatment for chronic Chagas disease in Milan, Italy. Clin Infect Dis. 2015;60(12):1873–1875.
   PubMed Web of Science ®Google Scholar
• González-Ramos J, Noguera-Morel L, Tong HY, et al. Two cases of overlap severe cutaneous adverse reactions to benznidazole treatment for asymptomatic Chagas disease in a nonendemic country. Br J Dermatol. 2016;175(3):604–607.
   PubMed Web of Science ®Google Scholar
• Viotti R, Vigliano C. Etiological treatment of chronic Chagas disease: neglected ‘evidence’ by evidence-based medicine. Expert Rev Anti Infect Ther. 2007;5(4):717–726.
   PubMed Web of Science ®Google Scholar
• Aldasoro E, Pinazo MJ, Oliveira I, et al. Arthritis and benznidazole: more closely related than we thought. Antimicrob Agents Chemother. 2015;59(1):727–729.
   PubMed Web of Science ®Google Scholar
• Da Silva GMS, Mediano MFF, Do Brasil PEAA, et al. A clinical adverse drug reaction prediction model for patients with chagas disease treated with benznidazole. Antimicrob Agents Chemother. 2014;58:6371–6377.
   PubMed Web of Science ®Google Scholar
• Salvador F, Sánchez-Montalvá A, Martínez-Gallo M, et al. Evaluation of cytokine profile and HLA association in benznidazole related cutaneous reactions in patients with Chagas disease. Clin Infect Dis. 2015;61:1688–1694.
   PubMed Web of Science ®Google Scholar
• Viotti R, Vigliano C, Lococo B, et al. Side effects of benznidazole as treatment in chronic Chagas disease: fears and realities. Expert Rev Anti Infect Ther. 2009;7(2):157–163.
   PubMed Web of Science ®Google Scholar
• Sosa-Estani S, Armenti A, Araujo G, et al. Treatment of Chagas disease with benznidazole and thioctic acid. Medicina (B Aires). 2004;64:1–6. [Article in Spanish]
   Google Scholar
• Galván IL, Pascual OM, Herrero-Martínez JM, et al. Does progressive introduction of benznidazole reduce the chance of adverse events in the treatment of chagas disease? Am J Trop Med Hyg. 2019;100(6):1477–1481.
   PubMed Web of Science ®Google Scholar
• Crespillo-Andújar C, López-Vélez R, Trigo E, et al. Comparison of the toxicity of two treatment schemes with benznidazole for chronic Chagas disease: a prospective cohort study in two Spanish referral centres. Clin Microbiol Infect. 2020;26(3):384.
   PubMed Web of Science ®Google Scholar
• Górgolas M, Robles I, Cabello A, et al. The use of steroids to prevent cutaneous reactions to benznidazole in patients with Chagas disease. Pathog Glob Health. 2013;107(3):157–160.
   PubMed Web of Science ®Google Scholar
• Puerta-Alcalde P, Gomez-Junyent J, Requena-Mendez A, et al. High prevalence of S. stercoralis infection among patients with Chagas disease: A retrospective case-control study. PLoS Negl Trop Dis. 2018;12(1):1–11.
   Web of Science ®Google Scholar
• DNDi. The BENDITA study: A Phase II study to assess safety, tolerability, and efficacy of different benznidazole regimens, alone and in combination with fosravuconazole [Internet]. 2019 [cited 2020 Jun 10]. Available from: https://www.dndi.org/wp-content/uploads/2019/03/2page_BenditatStudyOverview_ENG.pdf
   Google Scholar
• Corrêa VR, Barbosa FG, de Melo Junior CA, et al. Uneventful benznidazole treatment of acute Chagas disease during pregnancy: a case report. Rev Soc Bras Med Trop. 2014;47:397–400.
   PubMed Web of Science ®Google Scholar
• García-Bournissen F, Moroni S, Marson ME, et al. Limited infant exposure to benznidazole through breast milk during maternal treatment for Chagas disease. Arch Dis Child. 2015;100(1):90–94.
   PubMed Web of Science ®Google Scholar
• World Health Organization. World Health Organization model list of essential medicines: 21st list. 2019.
   Google Scholar
• Herwaldt BL, Dougherty CP, Allen CK, et al. Characteristics of patients for whom benznidazole was released through the CDC-sponsored investigational new drug program for treatment of Chagas disease — United States, 2011–2018. MMWR Morb Mortal Wkly Rep. 2018;67(29):803–805.
   PubMed Web of Science ®Google Scholar
• FDA approves first U.S. treatment for Chagas disease FDA. [ Internet]. [cited 2020 Jun 29]. Available from: https://www.fda.gov/news-events/press-announcements/fda-approves-first-us-treatment-chagas-disease.
   Google Scholar
• Estado plurinacional de Bolivia. Ministerio de salud y deportes. manual de normas para el diagnóstico y tratamiento de chagas congénito. serie documentos técnico normativos. 2011.
   Google Scholar
• Gobierno de Chile: Ministerio de Salud. Manual de procedimiento para la atención de pacientes con enfermedad de chagas. 2017.
   Google Scholar
• Republica de Colombia: Ministerio de la Protección Social. Guia de atencion clinica de la enfermedad de chagas 2010 (Documento actualizado de version convenio 256/09). 2010.
   Google Scholar
• Ministerio de Salud Pública Uruguay. Enfermedad de chagas. 2012.
   Google Scholar
• Subsecretaría de prevención y promoción de la salud de México. Manual de diagnóstico y tratamiento de la enfermedad de Chagas. 2015.
   Google Scholar
• Ministerio de Salud Pública de Ecuador. Manejo Etiológico de la Enfermedad de Chagas. 2017.
   Google Scholar
• Ministério da Saúde Brazil. Protocolo Clínico e Diretrizes Terapêuticas Doença de Chagas. 2018.
   Google Scholar
• Secretaría de Salud Honduras. Manual de normas y procedimientos para la prevención y control de la enfermedad de chagas. 2006.
   Google Scholar
• Pinazo MJ, Thomas MC, Bustamante J, et al. Biomarkers of therapeutic responses in chronic Chagas disease: state of the art and future perspectives. Mem Inst Oswaldo Cruz. 2015;110(3):422–432.
   PubMed Web of Science ®Google Scholar
• Pinazo M-J, Pinto J, Ortiz L, et al. A strategy for scaling up access to comprehensive care in adults with Chagas disease in endemic countries: the Bolivian Chagas platform. PLoS Negl Trop Dis. 2017;11(8): e0005770.
   PubMed Web of Science ®Google Scholar
• Pinazo MJ, Pereiro A, Herazo R, et al. Interventions to bring comprehensive care to people with Chagas disease: experiences in Bolivia, Argentina and Colombia. Acta Trop. 2020;203:105290.
   PubMed Web of Science ®Google Scholar